Last edition
News about "Vinita Gupta, CEO, Lupin"
Lupin to Present Phase 1 Data on LNP3693 (STING agonist) at ESMO Congress 2025
Lupin will present data from its Phase 1a clinical trial evaluating LNP3693, a STING agonist, at the ESMO Congress in Berlin, Germany, scheduled to be held from October 17 to October 21, 2025.
Vinita Gupta, CEO, Lupin | 13/10/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members